Abstract
The short chain fatty acid valproic acid (VPA, 2-propylpetanoic acid) is approved for the treatment of epilepsia, bipolar disorders and migraine and clinically used for schizophrenia. In 1999, the first clinical anti-cancer trial using VPA was initiated. Currently, VPA is examined in numerous clinical trials for different leukaemias and solid tumour entities. In addition to clinical assessment, the experimental examination of VPA as anti-cancer drug is ongoing and many questions remain unanswered. Although other mechanisms may also contribute to VPA-induced anti-cancer effects, inhibition of histone deacetylases appears to play a central role. This review focuses on recent developments regarding the anti-cancer activity of VPA.
Keywords: Valproic acid, HDAC, differentiation, angiogenesis, combination therapy, clinical studies
Current Pharmaceutical Design
Title: Valproic Acid As Anti-Cancer Drug
Volume: 13 Issue: 33
Author(s): Martin Michaelis, Hans Wilhelm Doerr and Jindrich Cinatl Jr.
Affiliation:
Keywords: Valproic acid, HDAC, differentiation, angiogenesis, combination therapy, clinical studies
Abstract: The short chain fatty acid valproic acid (VPA, 2-propylpetanoic acid) is approved for the treatment of epilepsia, bipolar disorders and migraine and clinically used for schizophrenia. In 1999, the first clinical anti-cancer trial using VPA was initiated. Currently, VPA is examined in numerous clinical trials for different leukaemias and solid tumour entities. In addition to clinical assessment, the experimental examination of VPA as anti-cancer drug is ongoing and many questions remain unanswered. Although other mechanisms may also contribute to VPA-induced anti-cancer effects, inhibition of histone deacetylases appears to play a central role. This review focuses on recent developments regarding the anti-cancer activity of VPA.
Export Options
About this article
Cite this article as:
Michaelis Martin, Doerr Wilhelm Hans and Cinatl Jr. Jindrich, Valproic Acid As Anti-Cancer Drug, Current Pharmaceutical Design 2007; 13 (33) . https://dx.doi.org/10.2174/138161207782360528
DOI https://dx.doi.org/10.2174/138161207782360528 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
A Review on Antiproliferative and Apoptotic Activities of Natural Honey
Anti-Cancer Agents in Medicinal Chemistry Embryonic Morphogenetic Field Induces Phenotypic Reversion in Cancer Cells. Review Article
Current Pharmaceutical Biotechnology Bisphosphonate Therapy in the Treatment of Multiple Myeloma
Current Pharmaceutical Design The Culture-Repopulating Ability Assays and Incubation in Low Oxygen: A Simple Way to Test Drugs on Leukaemia Stem or Progenitor Cells
Current Pharmaceutical Design Inhibitors of Cyclin Dependent Kinases: Useful Targets for Cancer Treatment
Current Cancer Drug Targets Analysis of the Molecular Determinants of the Response of Chronic Myelogenous Leukaemia to Tyrosine Kinase Inhibitors
Current Pharmacogenomics Machine Learning for Childhood Acute Lymphoblastic Leukaemia Gene Expression Data Analysis: A Review
Current Bioinformatics Platelet Activity in the Pathophysiology of Inflammatory Bowel Diseases
Current Drug Targets Performance of Feature Selection Methods
Current Genomics Biosafety of Onco-Retroviral Vectors
Current Gene Therapy CYP1A1 and CYP2D6 Polymorphisms and Susceptibility to Chronic Myelocytic Leukaemia
Current Cancer Drug Targets Purine Analogues as Kinase Inhibitors: A Review
Recent Patents on Anti-Cancer Drug Discovery Drug-Lipid Membrane Interaction Mechanisms Revealed Through Molecular Simulations
Current Physical Chemistry Epigenetic Remodeling of Chromatin Architecture: Exploring Tumor Differentiation Therapies in Mesenchymal Stem Cells and Sarcomas
Current Stem Cell Research & Therapy New Therapies for Patients with Chronic Lymphocytic Leukemia
Current Cancer Therapy Reviews Bioinorganic Chemistry: The Study of the Fate of Platinum-Based Antitumour Drugs
Current Chemical Biology Traditional Chinese Medicines (TCMs) for Molecular Targeted Therapies of Tumours
Current Drug Discovery Technologies Impact of Immunogenetic Polymorphisms in Bone Marrow Failure Syndromes
Mini-Reviews in Medicinal Chemistry n-3 Polyunsaturated Fatty Acids and the Prevention of Colorectal Cancer: Molecular Mechanisms Involved
Current Medicinal Chemistry Self-Renewal Versus Differentiation in Hematopoietic Stem and Progenitor Cells: A Focus on Asymmetric Cell Divisions
Current Stem Cell Research & Therapy